Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136539 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer
A Phase 2 study, sponsored by Harold J. Burstein, MD, PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00136539: Completed Phase 2 study, sponsored by Harold J. Burstein, MD, PhD.
NCT00136539 is a Phase 2 study that has completed, run by Harold J. Burstein, MD, PhD. The registered enrollment target is 41 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00136539, a Phase 2 study, has completed, sponsored by Harold J. Burstein, MD, PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness and safety of administering Herceptin in combination with Taxol (paclitaxel) in the treatment of women with HER2-positive, early stage breast cancer prior to surgery.
Interventions
- DRUG Cytoxan
- DRUG Taxol
- DRUG Adriamycin
- DRUG Herceptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 1999-03 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
What the finished NCT00136539 record still lists
NCT00136539 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 4 interventions - of which Cytoxan is the first listed.
NCT00136539 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00136539 about?
NCT00136539 is a clinical study titled "Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer". The purpose of this study is to determine the effectiveness and safety of administering Herceptin in combination with Taxol (paclitaxel) in the treatment of women with HER2-positive, early stage breast cancer prior to surgery.
What is the current status of trial NCT00136539?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 1999-03. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00136539?
The interventions under investigation include: Cytoxan (DRUG), Taxol (DRUG), Adriamycin (DRUG), Herceptin (DRUG).
Who is sponsoring clinical trial NCT00136539?
This trial is sponsored by Harold J. Burstein, MD, PhD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00136539's enrollment target sits among peer trials
41 1352nd of 2000 higher than 639 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia